Skip to nav Skip to content
Michael  Yu

Michael Yu, MD

4.9 (129)

Specialty: Radiation Oncology

Program: Radiation Oncology

Language(s): English

  • Overview

    Cancer Focus:
    Brain Cancer, Spinal Tumor

    Dr. Yu is board certified in Radiation Oncology and in Hospice and Palliative Medicine. His clinical interests include radiotherapy and stereotactic treatment for brain and spine tumors as well as radiotherapy for palliation to improve symptoms and quality of life in patients with advanced and metastatic cancers. His research interests focus on improving therapeutic outcomes using advanced radiation techniques including stereotactic radiosurgery and hypofractionated radiotherapy for brain and spine tumors. In addition, he has special interest in the integration of radiotherapy in palliative care to improve the quality and efficiency of palliative care.  

    Education & Training

    Residency:

    • Johns Hopkins Hospital - Radiation Oncology
    • Johns Hopkins Hospital - Radiation Oncology

    Medical School:

    • Robert Wood Johnson Medical School - MD
  • Participating Trials

    Clinical Trial 21193
    Pre-operative Hypofractionated Stereotactic Radiosurgery for Resectable Brain Metastases
    Condition: Neurologic Oncology
    Intervention: fSRS ()
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Tang JD, Mills MN, Nakashima J, Dohm AE, Khushalani NI, Forsyth PA, Vogelbaum MA, Wuthrick EJ, Yu HM, Oliver DE, Liu JKC, Ahmed KA. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery. J Neurooncol. 2024 Feb.166(3):431-440. Pubmedid: 38310157.
    • Ravi H, Hawkins SH, Stringfield O, Pereira M, Chen DT, Enderling H, Michael Yu HH, Arrington JA, Sahebjam S, Raghunand N. Rules-based Volumetric Segmentation of Multiparametric MRI for Response Assessment in Recurrent High-Grade Glioma. Res Sq. 2023 Sep. Pubmedid: 37790451. Pmcid: PMC10543497.
    • Dohm AE, Nakashima JY, Kalagotla H, Jiang SX, Tang JD, Bhandari M, Kim Y, Graham JA, Khushalani NI, Forsyth PA, Etame AB, Liu JK, Tran ND, Vogelbaum MA, Wuthrick EJ, Yu HM, Oliver DE, Ahmed KA. Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases. Eur J Cancer. 2023 Oct.192:113287. Pubmedid: 37657227.
    • Bryant JM, Doniparthi A, Weygand J, Cruz-Chamorro R, Oraiqat IM, Andreozzi J, Graham J, Redler G, Latifi K, Feygelman V, Rosenberg SA, Yu HM, Oliver DE. Treatment of Central Nervous System Tumors on Combination MR-Linear Accelerators: Review of Current Practice and Future Directions. Cancers (Basel). 2023 Oct.15(21). Pubmedid: 37958374. Pmcid: PMC10649155.
    • Keit E, Lee SF, Woodward M, Rembielak A, Shiue K, Desideri I, Oldenburger E, Bienz M, Rades D, Theodorou M, Agyeman MB, Yarney J, Bryant JM, Yu HM, Simone CB, Hoskin P, Johnstone PAS. Palliative whole brain radiation therapy: an international state of practice. Ann Palliat Med. 2023 Nov.12(6):1155-1164. Pubmedid: 37731303.
    • Wong HCY, Chan AW, Johnstone P, Simone CB, Navarro-Domenech I, Hoskin P, Johnstone C, Recht A, Menten J, van der Linden YM, van der Velden JM, Nguyen QN, Lutz S, Andratschke N, Wilmann J, Kazmierska J, Spalek M, Lim F, Yu HM, Perez B, Marta GN, Vassiliou V, Lee SF, Bonomo P, Rembielak A, Chow E, Oldenburger E, Raman S. A critical appraisal of the four systematic reviews and meta-analysis on stereotactic body radiation therapy versus external beam radiotherapy for painful bone metastases and where we go from here. Ann Palliat Med. 2023 Nov.12(6):1318-1330. Pubmedid: 37303218.
    • Khatri VM, Mills MN, Oliver DE, Yu HM, Vogelbaum MA, Forsyth PA, Soliman HH, Han HS, Ahmed KA. Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases. J Neurooncol. 2023 Aug.164(1):191-197. Pubmedid: 37490232.
    • Jiang S, Macaulay R, Ahmed K, Etame AB, Yu HM. Characterization of Immune Infiltrates Associated With Radiation Necrosis in the Setting of Brain Metastases Following Stereotactic Radiosurgery and Immunotherapy: A Retrospective Cohort Analysis. Cureus. 2023 Aug.15(8):e43528. Pubmedid: 37719517. Pmcid: PMC10501495.
    • Oliver DE, Yu HM, Ahmed KA. The Lung Graded Prognostic Assessment: Continued Evolution of Brain Metastases Prognostication. Int J Radiat Oncol Biol Phys. 2022 Sep.114(1):75-77. Pubmedid: 35964633.
    • Dohm AE, Tang JD, Mills MN, Liveringhouse CL, Sandoval ML, Perez BA, Robinson TJ, Creelan BC, Gray JE, Etame AB, Vogelbaum MA, Forsyth P, Yu HM, Oliver DE, Ahmed KA. Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone. J Neurosurg. 2022 Nov.1-8. Pubmedid: 36681988.
    • Brüningk SC, Peacock J, Whelan CJ, Brady-Nicholls R, Yu HM, Sahebjam S, Enderling H. Author Correction: Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements. Sci Rep. 2022 Mar.12(1):4441. Pubmedid: 35292722. Pmcid: PMC8924186.
    • Rubino S, Oliver DE, Tran ND, Vogelbaum MA, Forsyth PA, Yu HM, Ahmed K, Etame AB. Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies. Front Oncol. 2022 Mar.12:854402. Pubmedid: 35311078. Pmcid: PMC8924127.
    • Graham JA, Redler G, Delozier KB, Yu HM, Oliver DE, Rosenberg SA. Dosimetric feasibility of hippocampal avoidance whole brain radiotherapy with an MRI-guided linear accelerator. J Appl Clin Med Phys. 2022 Jun.23(6):e13587. Pubmedid: 35344266. Pmcid: PMC9195042.
    • Dohm AE, Oliver DE, Michael Yu HH, Ahmed KA. Commentary: From Postoperative to Preoperative: A Case Series of Hypofractionated and Single-Fraction Neoadjuvant Stereotactic Radiosurgery for Brain Metastases. Oper Neurosurg (Hagerstown). 2022 Jun.22(6):e283-e284. Pubmedid: 35404318.
    • Kutuk T, Grass GD, Oliver D, Mokhtari S, Sahebjam S, Kim S, Penagaricano J, Yu HM, Tran N, Etame A, Peterson JL, Forsyth P, Robinson T. Revisiting the Concept of Recurrence of Primary Central Nervous System Lymphomas After Complete Response to Methotrexate-Based Therapy: Periventricular Reseeding as the Predominant Mechanism of Recurrence. Adv Radiat Oncol. 2022 Jul.7(4):100940. Pubmedid: 35814853. Pmcid: PMC9260129.
    • Mills MN, Potluri TK, Kawahara Y, Fahey M, Figura NB, Soyano AE, Washington IR, Diaz R, Oliver DE, Yu HM, Etame AB, Vogelbaum MA, Czerniecki BJ, Arrington JA, Sahebjam S, Forsyth PA, Soliman HH, Han HS, Ahmed KA. The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs. Breast Cancer Res Treat. 2022 Jan.191(1):209-217. Pubmedid: 34669082.
    • Eroglu Z, Topcu TO, Yu HM, Margolin KA. How I treat brain metastases of melanoma. ESMO Open. 2022 Dec.7(6):100598. Pubmedid: 36274439. Pmcid: PMC9589018.
    • Lowe SR, Wang CP, Brisco A, Whiting J, Arrington J, Ahmed K, Yu M, Robinson T, Oliver D, Etame A, Tran N, Beer Furlan A, Sahebjam S, Mokhtari S, Piña Y, Macaulay R, Forsyth P, Vogelbaum MA, Liu JKC. Surgical and anatomic factors predict development of leptomeningeal disease in patients with melanoma brain metastases. Neurooncol. 2022 Aug.24(8):1307-1317. Pubmedid: 35092434. Pmcid: PMC9340645.
    • Fleming JL, Pugh SL, Fisher BJ, Lesser GJ, Macdonald DR, Bell EH, McElroy JP, Becker AP, Timmers CD, Aldape KD, Rogers CL, Doyle TJ, Werner-Wasik M, Bahary JP, Yu HM, D'Souza DP, Laack NN, Sneed PK, Kwok Y, Won M, Mehta MP, Chakravarti A. Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma. JCO Precis Oncol. 2021 Sep.5. Pubmedid: 34589661. Pmcid: PMC8462570.
    • Ahmed KA, Kim Y, Arrington JA, Kim S, DeJesus M, Soyano AE, Armaghani AJ, Costa RLB, Khong HT, Loftus LS, Rosa M, Caudell JJ, Diaz R, Robinson TJ, Etame AB, Tran ND, Sahebjam S, Soliman HH, Czerniecki BJ, Forsyth PA, Yu HM, Han HS. Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study. Adv Radiat Oncol. 2021 Sep.6(6):100798. Pubmedid: 34934864. Pmcid: PMC8655428.
    • Brüningk SC, Peacock J, Whelan CJ, Brady-Nicholls R, Yu HM, Sahebjam S, Enderling H. Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements. Sci Rep. 2021 Oct.11(1):20219. Pubmedid: 34642366. Pmcid: PMC8511136.
    • Mills MN, Naz A, Thawani C, Walker C, Figura NB, Kushchayev S, Oliver DE, Etame AB, Yu HM, Robinson TJ, Liu JKC, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Capecitabine and stereotactic radiation in the management of breast cancer brain metastases. BMC Cancer. 2021 May.21(1):552. Pubmedid: 33992087. Pmcid: PMC8126143.
    • Mills MN, Thawani C, Figura NB, Oliver DE, Soyano AE, Etame A, Robinson TJ, Liu JK, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Yu HM, Ahmed KA. Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases. J Neurooncol. 2021 May.152(3):591-601. Pubmedid: 33742358.
    • Mills MN, Walker C, Thawani C, Naz A, Figura NB, Kushchayev S, Etame A, Yu HM, Robinson TJ, Liu J, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. BMC Cancer. 2021 Mar.21(1):223. Pubmedid: 33663447. Pmcid: PMC7934378.
    • Koo J, Nardella L, Degnan M, Andreozzi J, Yu HM, Penagaricano J, Johnstone PAS, Oliver D, Ahmed K, Rosenberg SA, Wuthrick E, Diaz R, Feygelman V, Latifi K, Moros EG, Redler G. Triggered kV Imaging During Spine SBRT for Intrafraction Motion Management. Technol Cancer Res Treat. 2021 Jan.20. Pubmedid: 34855577. Pmcid: PMC8649431.
    • Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, Walko CM, Boyle T, Peguero EN, Jaglal M, Mokhtari S, Enderling H, Raghunand N, Gatewood T, Long W, Dzierzeski JL, Evernden B, Robinson T, Wicklund MC, Kim S, Thompson ZJ, Chen DT, Chinnaiyan P, Yu HM. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neurooncol. 2021 Apr.23(4):677-686. Pubmedid: 33173935. Pmcid: PMC8041351.
    • Johnstone PAS, Alla R, Yu HM, Portman D, Cheng H, Mitchell R, Jim H. Patient-reported outcomes: using ESAS to screen for anemia. Support Care Cancer. 2020 Sep.28(9):4141-4145. Pubmedid: 31872297. Pmcid: PMC7771327.
    • Sim AJ, Ahmed KA, Keller A, Figura NB, Oliver DE, Sarangkasiri S, Robinson TJ, Johnstone PAS, Yu HM, Naghavi AO. Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiation for Sarcoma Brain Metastases. Am J Clin Oncol. 2020 May.43(5):356-361. Pubmedid: 32217854.
    • Mohammadi H, Shiue K, Grass GD, Verma V, Engellandt K, Daubner D, Schackert G, Gondim MJ, Gondim D, Vortmeyer AO, Kamer AP, Jin W, Robinson TJ, Watson G, Yu HM, Lautenschlaeger T. Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience. Neurooncol Pract. 2020 Mar.7(2):185-195. Pubmedid: 32626587. Pmcid: PMC7318854.
    • Glazar DJ, Grass GD, Arrington JA, Forsyth PA, Raghunand N, Yu HM, Sahebjam S, Enderling H. Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade Glioma. J Clin Med. 2020 Jun.9(7). Pubmedid: 32605050. Pmcid: PMC7409184.
    • Fisher BJ, Pugh SL, Macdonald DR, Chakravatri A, Lesser GJ, Fox S, Rogers CL, Werner-Wasik M, Doyle T, Bahary JP, Fiveash JB, Bovi JA, Howard SP, Michael Yu HH, D'Souza D, Laack NN, Barani IJ, Kwok Y, Wahl DR, Strasser JF, Won M, Mehta MP. Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys. 2020 Jul.107(4):720-725. Pubmedid: 32251755. Pmcid: PMC7456814.
    • Nanda R, Boulware D, Baz R, Portman D, Yu HM, Jim H, Johnstone PAS. Patient-reported outcomes regarding radiation therapy in patients with multiple myeloma. Acta Oncol. 2020 Aug.59(8):983-987. Pubmedid: 32496846. Pmcid: PMC7771243.
    • Rishi A, Yu HM. Current Treatment of Melanoma Brain Metastasis. CURR TREAT OPTION ON. 2020 Apr.21(6):45. Pubmedid: 32350685.
    • Mills MN, Figura NB, Arrington JA, Yu HM, Etame AB, Vogelbaum MA, Soliman H, Czerniecki BJ, Forsyth PA, Han HS, Ahmed KA. Management of brain metastases in breast cancer: a review of current practices and emerging treatments. Breast Cancer Res Treat. 2020 Apr.180(2):279-300. Pubmedid: 32030570.
    • Johnstone PAS, Bulls HW, Zhou JM, Lee JK, Portman D, Yu HM, Jim H. Congruence of multiple patient-related outcomes within a single day. Support Care Cancer. 2019 Mar.27(3):867-872. Pubmedid: 30069695. Pmcid: PMC7771273.
    • Figura NB, Rizk VT, Mohammadi H, Evernden B, Mokhtari S, Yu HM, Robinson TJ, Etame AB, Tran ND, Liu J, Washington I, Diaz R, Czerniecki BJ, Soliman H, Han HS, Sahebjam S, Forsyth PA, Ahmed KA. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res Treat. 2019 Jun.175(3):781-788. Pubmedid: 30859348.
    • Figura NB, Potluri TK, Mohammadi H, Oliver DE, Arrington JA, Robinson TJ, Etame AB, Tran ND, Liu JK, Soliman H, Forsyth PA, Sahebjam S, Yu HM, Han HS, Ahmed KA. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases. J Neurooncol. 2019 Aug.144(3):583-589. Pubmedid: 31399935.
    • Vogelbaum MA, Yu HM. Nodular leptomeningeal disease after surgery for a brain metastasis-should we be concerned?. Neurooncol. 2019 Aug.21(8):959-960. Pubmedid: 31051044. Pmcid: PMC6682200.
    • Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP, Chakravarti A. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. JAMA Oncol. 2018 Oct.4(10):1405-1409. Pubmedid: 29955793. Pmcid: PMC6117103.
    • Figura N, Smith J, Yu HM. Mechanisms of, and Adjuvants for, Bone Pain. Hematol Oncol Clin North Am. 2018 Jun.32(3):447-458. Pubmedid: 29729780.
    • B Figura N, Long W, Yu M, Robinson TJ, Mokhtari S, Etame AB, Tran ND, Diaz R, Soliman H, S Han H, Sahebjam S, Forsyth PA, Ahmed KA. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat. 2018 Jun.169(2):391-396. Pubmedid: 29392582.
    • Wang JP, Yu HM, Chiang ER, Wang JY, Chou PH, Hung SC. Corticosteroid inhibits differentiation of palmar fibromatosis-derived stem cells (FSCs) through downregulation of transforming growth factor-β1 (TGF-β1). PLoS One. 2018 Jun.13(6):e0198326. Pubmedid: 29944666. Pmcid: PMC6019676.
    • Perez MC, Yu HM, Markowitz J. Severe thromboembolic phenomenon in the setting of pseudoprogression of melanoma brain metastases in response to combination immunotherapy. BMJ Case Rep. 2018 Aug.2018. Pubmedid: 30108120. Pmcid: PMC6101337.
    • Chinnaiyan P, Won M, Wen PY, Rojiani AM, Werner-Wasik M, Shih HA, Ashby LS, Yu HM, Stieber VW, Malone SC, Fiveash JB, Mohile NA, Ahluwalia MS, Wendland MM, Stella PJ, Kee AY, Mehta MP. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neurooncol. 2018 Apr.20(5):666-673. Pubmedid: 29126203. Pmcid: PMC5892159.
    • Choi CYH, Wakelee HA, Neal JW, Pinder-Schenck MC, Yu HM, Chang SD, Adler JR, Modlin LA, Harsh GR, Soltys SG. Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. Int J Radiat Oncol Biol Phys. 2017 Sep.99(1):16-21. Pubmedid: 28816142.
    • Yin CY, Yu HM, Wang JP, Huang YC, Huang TF, Chang MC. Long-term follow-up of Dupuytren disease after injection of triamcinolone acetonide in Chinese patients in Taiwan. J Hand Surg Eur Vol. 2017 Sep.42(7):678-682. Pubmedid: 28183220.
    • Johnstone PAS, Lee J, Zhou JM, Ma Z, Portman D, Jim H, Yu HM. A modified Edmonton Symptom Assessment Scale for symptom clusters in radiation oncology patients. Cancer Med. 2017 Sep.6(9):2034-2041. Pubmedid: 28776964. Pmcid: PMC5603842.
    • Ahmed KA, Kim S, Arrington J, Naghavi AO, Dilling TJ, Creelan BC, Antonia SJ, Caudell JJ, Harrison LB, Sahebjam S, Gray JE, Etame AB, Johnstone PA, Yu M, Perez BA. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol. 2017 Jun.133(2):331-338. Pubmedid: 28466250.
    • Ahmed KA, Berglund AE, Welsh EA, Naghavi AO, Kim Y, Yu M, Robinson TJ, Eschrich SA, Johnstone PA, Torres-Roca JF. The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity. Neurooncol. 2017 Aug.19(8):1145-1146. Pubmedid: 28379582. Pmcid: PMC5570253.
    • Abuodeh Y, Ahmed KA, Naghavi AO, Venkat PS, Sarangkasiri S, Johnstone PA, Etame AB, Yu HM. Postoperative Stereotactic Radiosurgery Using 5-Gy × 5 Sessions in the Management of Brain Metastases. World Neurosurg. 2016 Jun.90:58-65. Pubmedid: 26921701.
    • Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani NI, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol. 2016 Dec.27(12):2288-2294. Pubmedid: 27637745. Pmcid: PMC8890451.
    • Ahmed KA, Sarangkasiri S, Chinnaiyan P, Sahebjam S, Yu HH, Etame AB, Rao NG. Outcomes Following Hypofractionated Stereotactic Radiotherapy in the Management of Brain Metastases. Am J Clin Oncol. 2016 Aug.39(4):379-383. Pubmedid: 24755663.
    • Patel BG, Ahmed KA, Johnstone PA, Yu HM, Etame AB. Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Res. 2016 Aug.26(4):382-386. Pubmedid: 26926151.
    • Ahmed KA, Freilich JM, Abuodeh Y, Figura N, Patel N, Sarangkasiri S, Chinnaiyan P, Yu HH, Etame AB, Rao NG. Fractionated stereotactic radiotherapy to the post-operative cavity for radioresistant and radiosensitive brain metastases. J Neurooncol. 2014 May.118(1):179-186. Pubmedid: 24604750.
    • Chinnaiyan P, Chowdhary S, Potthast L, Prabhu A, Tsai YY, Sarcar B, Kahali S, Brem S, Yu HM, Rojiani A, Murtagh R, Pan E. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neurooncol. 2012 Jan.14(1):93-100. Pubmedid: 22028388. Pmcid: PMC3246000.
    • Yu HH, Hoffe SE. Beyond the conventional role of external-beam radiation therapy for skeletal metastases: new technologies and stereotactic directions. Cancer Control. 2012 Apr.19(2):129-136. Pubmedid: 22487975.
    • Yu HH, Tsai YY, Hoffe SE. Overview of diagnosis and management of metastatic disease to bone. Cancer Control. 2012 Apr.19(2):84-91. Pubmedid: 22487970.
    • Devito N, Yu M, Chen R, Pan E. Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. Anticancer Res. 2011 Dec.31(12):4537-4543. Pubmedid: 22199328.
    • Zhang GG, Ku L, Michael Yu HH, Sarangkasiri S, Zhang RR, Li W, Feygelman V. Dosimetric analysis of modulated and hybrid arcs in stereotactic radiosurgery. J Radiosurg SBRT. 2011.1(3):177-182. Pubmedid: 29296315. Pmcid: PMC5725314.
    • Yu M, Bui M, Gulati P, Masood S. Lipogranuloma. Breast J. 2001 Sep.7(5):363-364. Pubmedid: 11906448.
    • Yu M, Bui M, Bridges M, Masood S. Papillary carcinoma. Breast J. 2001 Jan.7(1):68-69. Pubmedid: 11348420.
  • Grants

    Title: Developing Mathematical Model Driven Optimized Recurrent Glioblastoma Therapies
    Sponsor: Nat Institutes of Health
    PI (Contact): Enderling, H., PI (MPI): Yu, M.
  • Patient Comments

    Overall Satisfaction

    4.9

    129 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey

     

    Comments

    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor